Edition:
United States

Dr.Reddy's Laboratories Ltd (RDY.N)

RDY.N on New York Stock Exchange

41.52USD
24 Jul 2017
Change (% chg)

$-0.94 (-2.21%)
Prev Close
$42.46
Open
$41.81
Day's High
$41.84
Day's Low
$41.42
Volume
203,213
Avg. Vol
61,215
52-wk High
$52.39
52-wk Low
$37.03

RDY.N

Chart for RDY.N

About

Dr. Reddy's Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and... (more)

Overall

Beta: 0.35
Market Cap(Mil.): $7,115.39
Shares Outstanding(Mil.): 165.82
Dividend: 0.31
Yield (%): 0.73

Financials

  RDY.N Industry Sector
P/E (TTM): 37.70 11.79 15.85
EPS (TTM): 1.13 -- --
ROI: 8.67 -10.04 -8.31
ROE: 9.54 -9.89 -7.95

BRIEF-Dr.Reddy's Labs says audit of Mexican plant by USFDA completed with zero observations

* Says audit of our API Cuernavaca plant at Mexico, by US FDA, has been completed with zero observations Source text for Eikon: Further company coverage:

Jul 21 2017

BRIEF-Dr. Reddy's Lab says USFDA issues form 483 with one observation for Srikakulam Plant

* Says formulations Srikakulam Plant (SEZ) unit I, Andhra Pradesh, by US FDA, has been completed Friday

Jun 16 2017

BRIEF-Dr.Reddy's Labs recalls Cipla-made zenatane capsule from U.S. markets

* Dr.Reddy's Laboratories clarifies on news item, "Dr Reddy's recalls 3.25l cartons Cipla-made acne drug from US".

Jun 15 2017

BRIEF-Dr.Reddy's Labs gets EIR as closure of audit of Miryalaguda API manufacturing plant

* Says got EIR after audit of API manufacturing plant at Miryalaguda, by US FDA, as closure of audit Source text - (http://bit.ly/2smE0VK) Further company coverage:

Jun 13 2017

BRIEF-Dr.Reddy's Laboratories announces launch of Bivalirudin for injection in U.S. market

* Says announces launch of Bivalirudin for injection in U.S. market Source text for Eikon: Further company coverage:

Jun 06 2017

BRIEF-Dr.Reddy's Labs' audit of formulations Srikakulum plant Unit II completed with zero observations

* Says audit of formulations Srikakulum Plant unit II, Andhra Pradesh by US FDA, completed with zero observations. Source text - (http://bit.ly/2qnkt2M) Further company coverage:

May 25 2017

BRIEF-Dr.Reddy's Laboratories says USFDA approved launch of doxorubicin hydrochloride liposome injection in U.S.

* Announces USFDA approval for launch of doxorubicin hydrochloride liposome injection in U.S. Market Source text - (http://bit.ly/2qQ6RC6) Further company coverage:

May 17 2017

BRIEF-India's Dr.Reddy's Laboratories March-qtr consol profit rises about three-fold

* Consensus forecast for March quarter consol profit was 4.27 billion rupees

May 12 2017

BRIEF-Dr. Reddy's Labs launches Ezetimibe and Simvastatin tablets in U.S. market

* Says launch of Ezetimibe and Simvastatin tablets in U.S. market Source text for Eikon: Further company coverage:

Apr 27 2017

BRIEF-Fresenius sees no change in relationship of Merck KGaA's unit with partner Dr Reddy's

* Fresenius ceo sturm says we've had a good q1 but will not provide details

Apr 25 2017

Earnings vs. Estimates